OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm Read more
Novartis Scemblix, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia Read more
Zerion Pharma and Insud Pharma announce collaboration to develop Dispersome formulations of marketed drug products Read more
Incyte Announces FDA Approval of Pemazyre (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement Read more
Sanyou Biopharmaceuticals and KangaBio established strategic collaboration to accelerate antibody drug development and innovation Read more
Bota Bio and Medichem Announce Commercial Development Collaboration to Advance Sustainable Pharmaceutical Manufacturing Read more